amcure leverages its exceptional knowledge of CD44 target biology to develop a pipeline of innovative therapeutic programs. In cancer, blocking the extracellular target CD44v6 could have a beneficial impact on several relevant receptor tyrosine kinase pathways. Using this unique approach, our lead compound, AMC303, has entered clinical development in solid tumors in Q4 2016.
Read More

Recent News

• 2019-03-28 amcure to Present Data on the Mode of Action of its Lead Compound AMC303 at the AACR Annual Meeting 2019. Please read the press release for more information.
• 2018-10-22 amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress. Please read the press release for more information.
• 2018-08-06 amcure Announces First Patient Dosed with AMC303 in Phase Ib Extension Cohort Based on Positive Safety Results. Please read the press release for more information.
• 2018-04-17 amcure Presents Pre-Clinical Anti-tumor and Anti-Metastatic Effects of AMC303 at AACR. Please read the press release for more information.
• 2018-01-15 amcure Appoints Biotech Executive Heinz Schwer to its Board. Please read the press release for more information.
• 2017-09-11 amcure Presents Phase I/Ib Study Design for Lead Compound AMC303 at ESMO 2017 Congress. Please read the press release for more information.
• 2017-08-31 amcure Receives Additional €1.75M BMBF Research Grant. Please read the press release for more information.

---

amcure is sponsored by a grant from the German Ministry of Education and Research
Short description: Development of a novel compound for the treatment of metastasizing cancers
Support code: 031B0052

read more